|
|
Expression of oligodendrocyte
progenitor cell antigens by gliomas: Implications for the histogenesis
of brain tumors
Yigal Shoshan, Akiko Nishiyama,
Ansi Chang, Sverre Mörk, Gene H. Barnett, John K. Cowell, Bruce D.
Trapp, and Susan M. Staugaitis
Department of Neurosciences, The
Lerner Research Institute [Y.S.*, G.H.B., J.K.C, S.M.S.°], and
Department of Neurosurgery, Cleveland Clinic Foundation, Cleveland, OH
44195 [Y.S., A.N.**, A.C., S.M., J.K.C., B.D.T., S.M.S.]. Communicated
by George R. Stark, Cleveland Clinic Foundation, Cleveland, OH,
June 29, 1999 (received for review March 8, 1999). *Present
address: Department of Neurosurgery, Hadassah University Hospital,
Jerusalem, Israel 91120. **Present address: Department of
Physiology and Neurobiology, University of Connecticut, Storrs, CT
06269. °To whom reprint requests should be addressed at:
Department of Neurosciences #NC30, Cleveland Clinic Foundation, 9500 Euclid
Avenue, Cleveland, OH 44195. E-mail: staugas@ccf.org.
The early events in neoplastic
transformation can be understood only by comparison of the neoplastic
cell with its nontransformed counterpart.
The most common central nervous system gliomas traditionally are
thought to arise from mature astrocytes and oligodendrocytes.
We examined the possibility that gliomas arise from a population of
glia that has properties of oligodendrocyte progenitors.
These glial cells express the NG2 chondroitin sulfate
proteoglycan and the α receptor of
platelet-derived growth factor in vivo.
We identified NG2 and the α receptor of
platelet-derived growth factor expression in tissue from
seven of seven oligodendrogliomas, three of three pilocytic
astrocytomas, and one of five glioblastoma multiforme.
These data provide evidence that glial tumors arise from glial progenitor
cells.
Molecules expressed by these progenitor cells should be
considered as targets for novel therapeutics.
Copyright © 1999 by The National
Academy of Sciences
|
